

Charge Redistribution in Adenosylribosyl Transferase Caused by Substitution of a Single Amino Acid Residue

Mary Gianniosis^a, Valerio Berardi^b, Adalberto Bonincontro^c, Eric Dabbs^a, and Gianfranco Risuleo^{b,c,*}

^a School of Molecular and Cell Biology, University of Witwatersrand, Johannesburg, South Africa

^b Dipartimento di Genetica e Biologia Molecolare, Università di Roma "La Sapienza", P. le A. Moro, 5, I-00185 Roma, Italy

^c CNISM and SOFT-INFN-CNR Research Center, Dipartimento di Fisica, Università di Roma "La Sapienza", P. le A. Moro, 5, I-00185 Roma, Italy.
E-mail: gianfranco.risuleo@uniroma1.it

* Author for correspondence and reprint requests

Z. Naturforsch. **63c**, 889–892 (2008); received March 28/May 13, 2008

Dielectric measurements in the frequency range 10^5 – 10^8 Hz were performed on wild-type (wt) adenosylribosyl transferase and a mutant enzyme. The analysis of the dielectric relaxation curve allowed the estimation of the hydrodynamic radius and of the electric dipole moment. The first parameter remained unchanged in wt and mutant protein. The dipole moment of the mutant, however, was significantly increased. Implications on the electrostatic interactions between enzyme and substrate are discussed.

Key words: Adenosylribosyl Transferase, Dielectric Spectroscopy, Protein Structure

Introduction

Rifamycins are the principal group of antimicrobials which inhibit prokaryotic transcription and are extensively used to combat *Mycobacterium tuberculosis* infections (Woodley *et al.*, 1972). This group consists of a number of related compounds biosynthesized by *Amycolatopsis mediterranei* (Lancini and Parenti, 1978); the genes responsible were cloned and characterized (Schupp *et al.*, 1998; Tang *et al.*, 1998). These natural products have been modified to enhance efficacy: rifampicin is the most widely used, but other examples are rifabutin, rifapentene, and rifamixin (Sensi, 1983). Rifampicin binds to the DNA-dependent RNA polymerase and blocks the elongation of the RNA (Wehrli and Staehelin, 1971). Another response to rifampicin in mycobacteria and related species is its inactivation, the drug being decomposed (Dabbs, 1991). Subsequently, two additional inactivation mechanisms were identified: glucosylation by *Nocardia brasiliensis* (Yazawa *et al.*, 1993) and phosphorylation by *Nocardia otitidiscaviarum* (Yazawa *et al.*, 1994). Another mechanism, ri-

bosylation, was first observed in *Mycobacterium smegmatis*. It was shown that this ribosylation consisted of a two-step biochemical reaction after the initial formation of an ADP-ribosylated drug (Dabbs *et al.*, 1995). The ADP-ribosyl transferase (*arr*) enzyme consists of 143 amino acid residues and is unusually thermostable (Quan *et al.*, 1997), although highly photosensitive. Disruption of the *arr* gene in *M. smegmatis* resulted in susceptibility increasing by 12- to 15-fold, showing that this gene product does contribute to the quite high *in vivo* rifampicin MIC (Dabbs and Quan, 2000).

Considering the relatively little knowledge about the chemico-physical properties of this protein, so important in antibiotic inactivation, we decided to gain an insight into this particular aspect adopting a well established biophysical approach. This is based on dielectric spectroscopy which provides information on the conformational structure of the protein and on protein-nucleic acid interactions (Bonincontro and Risuleo, 2003, 2005).

Experimental

Error-prone PCR mutagenesis

PCR was performed in a MJ MINITM thermal cycler (Bio-Rad Laboratories Ltd., Johannesburg, South Africa). The template was the *arr* ORF,

While this manuscript was processed an interesting article related to *arr* structure and diversity was published by Baysarowich J. (2008), Proc. Natl. Acad. Sci. USA **105**, 4886–4891.

Fig. 1. (A) Wild-type (wt) and (B) mutant (Mut) amino acid sequences. The proline-threonine substitution is evidenced as well as the DNA transversion. The mutation was ascertained by destruction of the restriction site.

change. As a matter of fact both amino acids are chiral, but the proline side chain is constituted by a closed ring formed by three $-\text{CH}_2$ groups linking the α -C to the N atom in the amino group. Threonine, on the other hand, has an aliphatic side chain containing an $-\text{OH}$ group. Interestingly, this hydroxy group may be modified by glucosylation. This side-chain modification is involved in rifampicin de-toxication in two different bacteria of the *Nocardia* genus (Yazawa *et al.*, 1993, 1994). It should be noted, however, that the amino acid substitution caused in our mutant did not result in a reduced rifampicin MIC in *E. coli* DH5 α (not shown).

The hypothesis, that mutagenesis may result in a structural alteration of the enzyme, was probed by dielectric spectroscopy, a strategy successfully used in our laboratory to investigate biomacromolecules (Bonincontro and Risuleo, 2003, 2005). Fig. 2 shows the result of the dielectric measurements performed on wild-type (wt) and pMG1 mutant protein in solution.

Data were fitted with the real part and imaginary part of the Cole-Cole equation




Fig. 2. Dielectric dispersion of protein suspensions at 20.0 °C. Data are reported as $\epsilon' - \epsilon_\infty$ vs. f , in Hz, in semi-logarithmic scale. Circles, wild-type protein; dots, mutant protein. In the inset the respective imaginary spectra are reported.

$$\epsilon = \epsilon_\infty + \frac{\Delta\epsilon}{1 + \left(i \frac{f}{f^*}\right)^{(1-\alpha)}}, \quad (1)$$

where ϵ is the complex dielectric constant, f is the measuring frequency, f^* is the relaxation frequency, i is the imaginary unit, $\Delta\epsilon$ is the dielectric increment, ϵ_∞ is the value of ϵ' extrapolated at high frequency, and α is an empirical parameter taking into account a spread of relaxation times (Hasted, 1973). The electric dipole moment, μ , of the protein was estimated from the dielectric increment, $\Delta\epsilon$, using the Oncley formula

$$\mu^2 = \frac{2\epsilon_0 M k T \Delta\epsilon}{N c g}, \quad (2)$$

where M is the protein molecular mass expressed in kDa, T is the temperature expressed in K, while k is the Boltzmann constant, ϵ_0 is the vacuum dielectric constant, N is the Avogadro number, c is the protein concentration expressed in mg/ml, and g is the molecular correlation parameter generally assumed as unit factor in dilute protein solutions (Pethig, 1979; Pethig and Kell, 1987).

The effective hydrodynamic radius, r , of the protein was calculated from the relaxation frequency, f^* , using the equation

$$f^* = \frac{kT}{8\pi^2 \eta r^3}, \quad (3)$$

where η is the viscosity of the solvent (Grant *et al.*, 1978).

The results of this analysis are reported in Table I. The estimated hydrodynamic radius for the wt enzyme appears rather large for a globular protein of this molecular weight. For instance, lysozyme with a comparable molecular weight has a hydrodynamic radius of 2 nm. This means that the rota-

Table I. Results of the Cole-Cole best fit of the experimental data. The concentration, the calculated apparent hydrodynamic radius and electric dipole moment are also presented. pGM1 is the recombinant plasmid encoding the mutant DNA sequence.

Sample	c [mg/ml]	$\Delta\epsilon$	f^* [MHz]	α	r [nm]	μ [D]
Wild-type	1.83	7.0 ± 0.8	0.72 ± 0.09	0.17 ± 0.09	4.1 ± 0.2	810 ± 40
pMG1	1.35	16 ± 2	0.8 ± 0.1	0.30 ± 0.04	4.0 ± 0.2	1420 ± 70

tional coefficient of diffusion is influenced by a form factor, which suggests a pronounced elongated shape for the three-dimensional conformation of the protein. In the mutant *arr* enzyme this conformational parameter does not seem to be affected. On the other hand, the dipole moment is significantly modified. As a matter of fact, the pattern of the relaxation curve clearly shows that the mutant protein has a much higher dielectric increment as compared to the wt enzyme. The dielectric increment is proportional to the concentration. Since the concentration of the mutant protein is lower, the actual effect on $\Delta\epsilon$ is much higher in reality. The value of μ in the mutant increases by about 75% (see Table I). Considering that the estimated hydrodynamic radius is almost constant, the variation of the dipole moment must be attributed exclusively to a drastic redistribution of the sur-

face charges. The increase of the dipole moment is consistent with a significantly higher physical separation of the electric charges.

In conclusion, in this short communication we presented evidence of a significant structural alteration of the *arr* protein. The dramatic charge redistribution, as demonstrated by dielectric spectroscopy, is due to a single amino acid substitution which apparently does not affect the enzyme-substrate interaction. The results presented here could be of significance for investigators of the mechanisms of drug inactivation mediated by this enzyme.

Acknowledgements

E. D. and G. R. obtained a traveling grant for an exchange program from the National Research Foundation (South Africa) and the Ministry of Foreign Affairs (Italy).

- Athey T. W., Stuckly M. A., and Stuckly S. S. (1982), Measurement of radio frequency permittivity of biological tissues with an open-ended coaxial line: Part I. *IEEE Trans.* **30**, 82–86.
- Bonincontro A. and Risuleo G. (2003), Dielectric spectroscopy as a probe for the investigation of conformational properties of proteins. *Spectrochim. Acta A: Mol. Biomol. Spectrosc.* **59**, 2677–2684.
- Bonincontro A. and Risuleo G. (2005), Structural studies of *E. coli* ribosomes by spectroscopic techniques: a specialized review. *Spectrochim. Acta A: Mol. Biomol. Spectrosc.* **62**, 1070–1080.
- Bonincontro A., Briganti G., Giansanti A., Pedone F., and Risuleo G. (1996), Electrical conductivity and dielectric dispersion of *E. coli* ribosomes and of 30S and 50S ribosomal subunits: effect of magnesium ions. *Colloids Surf. B: Biointerfaces* **6**, 219–223.
- Cadwell R. C. and Joyce R. F. (1992), Randomization of genes by PCR mutagenesis. *PCR Methods Appl.* **2**, 28–33.
- Dabbs E. R. (1991), Cloning of nocardioform DNA conferring the ability to inactivate rifampicin. *FEMS Microbiol. Lett.* **63**, 247–250.
- Dabbs E. R. and Quan S. (2000), Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene. *FEMS Microbiol. Lett.* **182**, 105–109.
- Dabbs E. R., Yazawa K., Mikami Y., Miyaji M., Morisaki N., Iwasaki S., and Furihata K. (1995), Ribosylation by mycobacterial strains as a new mechanism of rifampicin inactivation. *Antimicrob. Agents Chemother.* **39**, 1007–1009.
- Grant E. H., Sheppard R. J., and South G. P. (1978), *Dielectric Behavior of Biological Molecules in Solution*. Clarendon, Oxford.
- Hasted J. B. (1973), *Aqueous Dielectrics*. Chapman & Hall, London.
- Lancini G. C. and Parenti F. (1978), Rifamycin biogenesis. In: *Antibiotics and Other Secondary Metabolites Biosynthesis and Production* (Hütter R., Leisinger T., Nüesch J., and Wehrli W., eds.). Academic Press, London, pp. 129–139.
- Pethig R. (1979), *Dielectric and Electronic Properties of Biological Materials*. Wiley, New York.
- Pethig R. and Kell D. B. (1987), The passive electrical properties of biological systems: Their significance in physiology, biophysics and biotechnology. *Phys. Med. Biol.* **32**, 933–970.
- Quan S., Venter H., and Dabbs E. R. (1997), Ribosylative inactivation of rifampin by *Mycobacterium smegmatis* is a principal contributor to its low susceptibility to this antibiotic. *Antimicrob. Agents Chemother.* **41**, 2456–2460.
- Schupp T., Toupet C., Engel N., and Goff S. (1998), Cloning and sequence analysis of the putative rifamycin polyketide synthase gene cluster from *Amycolatopsis mediterranei*. *FEMS Microbiol. Lett.* **159**, 201–207.
- Sensi P. (1983), History of the development of rifampin. *Rev. Infect. Dis.* **5**, 402–406.
- Tang L., Yoon Y. J., Choi C. Y., and Hutchinson C. R. (1998), Characterization of the enzymatic domains in the modular polyketide synthase involved in rifamycin B biosynthesis by *Amycolatopsis mediterranei*. *Gene* **216**, 255–265.
- Wehrli W. and Staehelin M. (1971), Actions of the rifamycins. *Bact. Rev.* **35**, 290–308.
- Woodley C. L., Kilburn J. O., David H. L., and Silcox V. A. (1972), Susceptibility of mycobacteria to rifampin. *Antimicrob. Agents Chemother.* **2**, 245–249.
- Yazawa K., Mikami Y., Maeda N., Akao M., Morisaki N., and Iwasaki S. (1993), Inactivation of rifampin by *Nocardia brasiliensis*. *Antimicrob. Agents Chemother.* **37**, 1313–1317.
- Yazawa K., Mikami Y., Maeda A., Morisaki N., and Iwasaki S. (1994), Phosphorylative inactivation of rifampicin by *Nocardia otitidiscaviarum*. *J. Antimicrob. Chemother.* **33**, 1127–1135.